OPKO Health (NASDAQ:OPK) Posts Earnings Results, Hits Expectations

OPKO Health (NASDAQ:OPK) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07), FiscalAI reports. The company had revenue of $130.83 million for the quarter, compared to analyst estimates of $136.62 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%. The firm’s revenue for the quarter was down 56.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.03 EPS.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO agreed to sell substantially all of BioReference’s remaining operations to Labcorp for about $722 million in cash, with potential 4Kscore royalties of up to $150 million over 10 years. The deal, which remains subject to customary closing conditions, would complete OPKO’s exit from diagnostics and refocus it on biotech and global products.
• Continuing-operations revenue rose 16% to $65.4 million year over year, led by OPKO Iberoamerica, RAYALDEE and mazdutide royalties. Global products reported $6 million of operating income, versus a $1.2 million loss a year earlier.
• Pipeline programs advanced, including completion of enrollment in the planned phase I cohorts for MDX-2301, with management describing its blinded safety profile as favorable. OPKO is preparing subcutaneous dosing studies for several ModeX candidates, while its first in vivo CAR-T program is now targeted for first-in-human studies in mid-2027, later than previously planned.
• Innovative biotech’s operating loss widened to $26.8 million from $22.5 million, as increased research and development activity raised costs. OPKO expects about $125 million in BioReference sale-related costs, and forecast a roughly $40 million loss from discontinued operations in Q4.
• OPKO ended the quarter with $403.2 million in cash, cash equivalents and restricted cash, and repurchased 7.2 million shares for $10.6 million. It withdrew consolidated full-year guidance and issued continuing-operations revenue guidance of $268 million–$278 million; management said it would provide more detail on capital allocation as the Labcorp closing approaches.

OPKO Health Price Performance

Shares of OPK traded up $0.05 during mid-day trading on Wednesday, reaching $1.77. 4,819,446 shares of the stock traded hands, compared to its average volume of 5,615,405. The firm has a fifty day moving average price of $1.58 and a 200 day moving average price of $1.35. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -19.67 and a beta of 1.52. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.81.

Wall Street Analyst Weigh In

Several brokerages have commented on OPK. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. Zacks Research raised OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a research report on Friday, October 16th. Barrington Research raised shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price target on the stock in a report on Friday, October 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $4.00 price objective (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $3.42.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.